Synaptogenix Stock Today
| SNPX Stock | USD 2.60 0.03 1.17% |
Performance0 of 100
| Odds Of DistressOver 80
|
Synaptogenix is trading at 2.60 as of the 23rd of November 2024; that is 1.17 percent increase since the beginning of the trading day. The stock's open price was 2.57. Synaptogenix has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Synaptogenix are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 24th of October 2024 and ending today, the 23rd of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 8th of December 2020 | Category Healthcare | Classification Health Care |
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company was incorporated in 2012 and is headquartered in New York, New York. Synaptogenix operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 1.36 M outstanding shares of which 5.46 K shares are at this time shorted by private and institutional investors with about 0.17 trading days to cover. More on Synaptogenix
Moving together with Synaptogenix Stock
Moving against Synaptogenix Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Synaptogenix Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Chief President | Daniel MD | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Synaptogenix (SNPX) is traded on NASDAQ Exchange in USA. It is located in 1185 Avenue of the Americas, New York, NY, United States, 10036 and employs 5 people. Synaptogenix is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.07 M. Synaptogenix conducts business under Biotechnology sector and is part of Health Care industry. The entity has 1.36 M outstanding shares of which 5.46 K shares are at this time shorted by private and institutional investors with about 0.17 trading days to cover.
Synaptogenix currently holds about 28.75 M in cash with (5.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.2, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Synaptogenix Probability Of Bankruptcy
Ownership AllocationAbout 97.77 % of Synaptogenix outstanding shares are held by general public with 1.94 (%) owned by insiders and only 0.29 % by institutional holders.
Check Synaptogenix Ownership Details
Synaptogenix Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Ubs Group Ag | 2024-06-30 | 2.1 K | |
| Tower Research Capital Llc | 2024-06-30 | 1.8 K | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 180 | |
| Blackrock Inc | 2024-06-30 | 29.0 | |
| Bank Of America Corp | 2024-06-30 | 9.0 | |
| Royal Bank Of Canada | 2024-06-30 | 4.0 | |
| 1832 Asset Management L.p | 2024-09-30 | 0.0 | |
| Platform Technology Partners | 2024-06-30 | 0.0 |
Synaptogenix Historical Income Statement
Synaptogenix Stock Against Markets
Synaptogenix Corporate Executives
Elected by the shareholders, the Synaptogenix's board of directors comprises two types of representatives: Synaptogenix inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Synaptogenix. The board's role is to monitor Synaptogenix's management team and ensure that shareholders' interests are well served. Synaptogenix's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Synaptogenix's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert Weinstein | Executive CFO | Profile |
Additional Tools for Synaptogenix Stock Analysis
When running Synaptogenix's price analysis, check to measure Synaptogenix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Synaptogenix is operating at the current time. Most of Synaptogenix's value examination focuses on studying past and present price action to predict the probability of Synaptogenix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Synaptogenix's price. Additionally, you may evaluate how the addition of Synaptogenix to your portfolios can decrease your overall portfolio volatility.